Rakuten Medical, Inc. announced that it has received $100 million in a round of funding led by new investor, TaiAx Life Science Fund L.P., a fund managed by TaiAx Capital L.P. on January 7, 2026. The transaction included participation from new investors, NEXUS CVC Partners Corporation, ABIES Capital Co., Ltd., Orient EuroPharma Co., Ltd., MS&AD Insurance Group Holdings, Inc., Daiwa Securities Group Inc., Sumitomo Mitsui Financial Group, Inc., returning investors, Rakuten Ventures, SBI Holdings, Inc., Investment Arm and individual investor, Mickey Mikitani. The company issued a mix of debt and equity.